재발성 또는 난치성 소세포폐암에 대한 topotecan, vincristine 복합요법 Combination chemotherapy with topotecan and vincristine for patients with refractory or recurrent small cell lung cancer원문보기
목적 : 항암화학요법에 불응하거나 또는 관해 후 재발된 소세포폐암 환자를 대상으로 topotecan과 vincristine 복합화학요법의 효과와 안전성에 대하여 알아보기 위하여 연구를 시행하였다. 방법 : 조직학적으로 증명된 소세포폐암 환자로 이전 항암화학요법에 불응하거나 관해 후 재발된 환자를 대상으로 연구를 진행하였다. 치료는 topotecan 1.5mg/m2/day를 3일간, vincristine 1.5 mg/m2 (maximum 2 mg)를 홀수 주기에는 2일간, 짝수 주기에는 1일간 투여하였다. 이 치료는 감내할 수 없는 독성이 발생하거나 병변이 진행될 때까지 3주 간격으로 반복하였다. 결과 : 총 19예가 이 연구에 등록 되었다. 등록된 환자 연령의 중앙값은 63세이었다. 평가 가능한 19예 중 3예에서 부분관해가 관찰되어 반응률은 15.8% (95% 신뢰구간: 0~32.5%)이었다. 생존기간의 중앙값은 199일이었고, 진행까지의 기간 중앙값은 51일이었다. 전체 52회의 치료 중 NCI-CTC 3도 이상의 백혈구감소가 25.0%, 호중구감소가 11.5%에서 나타났다. NCI-CTC 2도의 신경독성이 15.4%에서 관찰되었으나 치료와 연관된 사망은 관찰되지 않았다. 결론 : 난치성 또는 재발성 소세포폐암에서 topotecan과 vincristine 복합화학요법은 효과가 있었고 안전하였다. 그러나 topotecan 단독요법과의 비교연구가 필요하다고 생각된다.
목적 : 항암화학요법에 불응하거나 또는 관해 후 재발된 소세포폐암 환자를 대상으로 topotecan과 vincristine 복합화학요법의 효과와 안전성에 대하여 알아보기 위하여 연구를 시행하였다. 방법 : 조직학적으로 증명된 소세포폐암 환자로 이전 항암화학요법에 불응하거나 관해 후 재발된 환자를 대상으로 연구를 진행하였다. 치료는 topotecan 1.5mg/m2/day를 3일간, vincristine 1.5 mg/m2 (maximum 2 mg)를 홀수 주기에는 2일간, 짝수 주기에는 1일간 투여하였다. 이 치료는 감내할 수 없는 독성이 발생하거나 병변이 진행될 때까지 3주 간격으로 반복하였다. 결과 : 총 19예가 이 연구에 등록 되었다. 등록된 환자 연령의 중앙값은 63세이었다. 평가 가능한 19예 중 3예에서 부분관해가 관찰되어 반응률은 15.8% (95% 신뢰구간: 0~32.5%)이었다. 생존기간의 중앙값은 199일이었고, 진행까지의 기간 중앙값은 51일이었다. 전체 52회의 치료 중 NCI-CTC 3도 이상의 백혈구감소가 25.0%, 호중구감소가 11.5%에서 나타났다. NCI-CTC 2도의 신경독성이 15.4%에서 관찰되었으나 치료와 연관된 사망은 관찰되지 않았다. 결론 : 난치성 또는 재발성 소세포폐암에서 topotecan과 vincristine 복합화학요법은 효과가 있었고 안전하였다. 그러나 topotecan 단독요법과의 비교연구가 필요하다고 생각된다.
Background : Small cell lung cancer (SCLC) is a chemotherapy-sensitive tumor. However, the duration of response is usually short and most patients experience relapses. Topotecan is commonly used for treatment of these patients. Nevertheless, the response rate of topotecan as a single regimen is only...
Background : Small cell lung cancer (SCLC) is a chemotherapy-sensitive tumor. However, the duration of response is usually short and most patients experience relapses. Topotecan is commonly used for treatment of these patients. Nevertheless, the response rate of topotecan as a single regimen is only about 20% and the resulting severe myelosuppression is troublesome. Vincristine is also an active agent, and it does not compromise the marrow function. In this background, we evaluated the efficacy and toxicities of topotecan and vincristine combination chemotherapy. Methods : Patients with pathologically confirmed SCLC refractory to or recurrent after platinum-based chemotherapy were eligible for this study. The treatment regimen was as follows; topotecan 1.5 mg/m2/day IV bolus on day 1, 2 and 3 and vincristine 1.5 mg/m2 (maximum 2 mg on day 1 (on every cycle)) and day 2 (on odd cycles only). This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of response rate, time to progression and overall survival duration. The toxicities were assessed according to NCI-CTC version 3.0. Results : A total of 19 patients were entered into this study. The median age was 63 years (range 43-85 years). Partial response was obtained for 3 patients (response rate 15.8%, 95% CI: 0-32.5%). The median time to progression and survival duration was 51 days and 199 days, respectively. For a total of 52 cycles of treatment, grade 3 or 4 neutropenia and thrombocytopenia were observed in 25.0% and 11.5% of the patients, respectively. Grade 2 neurotoxicities were observed in 15.4% of the patients. There was no treatment-related mortality. Conclusions : The topotecan and vincritine combination is active and safe for patients with recurrence or refractory SCLC. However, the benefit of adding vincristine to topotecan needs to be confirmed in further studies.
Background : Small cell lung cancer (SCLC) is a chemotherapy-sensitive tumor. However, the duration of response is usually short and most patients experience relapses. Topotecan is commonly used for treatment of these patients. Nevertheless, the response rate of topotecan as a single regimen is only about 20% and the resulting severe myelosuppression is troublesome. Vincristine is also an active agent, and it does not compromise the marrow function. In this background, we evaluated the efficacy and toxicities of topotecan and vincristine combination chemotherapy. Methods : Patients with pathologically confirmed SCLC refractory to or recurrent after platinum-based chemotherapy were eligible for this study. The treatment regimen was as follows; topotecan 1.5 mg/m2/day IV bolus on day 1, 2 and 3 and vincristine 1.5 mg/m2 (maximum 2 mg on day 1 (on every cycle)) and day 2 (on odd cycles only). This regimen was repeated every 3 weeks. The efficacy was evaluated in terms of response rate, time to progression and overall survival duration. The toxicities were assessed according to NCI-CTC version 3.0. Results : A total of 19 patients were entered into this study. The median age was 63 years (range 43-85 years). Partial response was obtained for 3 patients (response rate 15.8%, 95% CI: 0-32.5%). The median time to progression and survival duration was 51 days and 199 days, respectively. For a total of 52 cycles of treatment, grade 3 or 4 neutropenia and thrombocytopenia were observed in 25.0% and 11.5% of the patients, respectively. Grade 2 neurotoxicities were observed in 15.4% of the patients. There was no treatment-related mortality. Conclusions : The topotecan and vincritine combination is active and safe for patients with recurrence or refractory SCLC. However, the benefit of adding vincristine to topotecan needs to be confirmed in further studies.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.